Other AP Flashcards
(145 cards)
3 types of cytosolic fibers in the cytoskeleton?
The cytoskeleton consists of 3 types of cytosolic fibers: microfilaments (actin filaments), intermediate filaments, and microtubules.
Adjuvant, neoadjuvant, induction, consolidation, maintenance, first line, second line chemotherapy?
Adjuvant chemo is given to destroy leftover (microscopic) cancer that may be present after the known tumor is removed by surgery (primary therapy). Is given to prevent a possible cancer recurrence. If known disease is left behind at surgery, further treatment is technically not adjuvant. Neoadjuvant chemo is given prior to the surgical procedure in an attempt to shrink the tumor so that the surgical procedure may not have to be as extensive. Induction chemo is given to induce a remission. The term is commonly used in the treatment of acute leukemias. Consolidation chemo (also called intensification therapy) is given once remission is achieved. The goal is to sustain the remission. The term is commonly used in the treatment of acute leukemias. Maintenance chemo is chemo given in lower doses to assist in prolonging a remission. Is used only for certain types of cancer, MC ALLs and APLs. First line chemo (also called standard therapy) is chemo that has been determined to have the best probability of treating a given cancer. Second line chemo (also called salvage therapy) is chemo that is given if a disease has not responded or has recurred after first line chemo.
Describe intracytoplasmic inclusions found in sarcoidosis.
ASTEROID BODIES: Small, eosinophilic, star-shaped structures. SCHAUMANN BODIES: Calcium and protein inclusions inside of Langerhans giant cells as part of a granuloma; basophilic, concentrically laminated, calcified, rounded chonchoidal structures. If numerous or large, they may be extruded into extracellular space.
CALCIUM OXALATE CRYSTALS: may serve as a nidus for deposition of calcium leading to formation of Schaumann bodies. HAMAZAKI-WESENBERG BODIES: PAS-positive inclusions which may be giant lysosomes containing lipofuscin or hemolipofuscin. Although H-W bodies may occur as inclusions, they are also found extracellularly in the sinusoids of lymph nodes in sarcoidosis. Are oval or spindle-shaped, range up to several microns in size, and appear yellow-brown with H&E. Stain with acid-fast and silver stains (may be mistaken for fungus). ADDITIONAL POINTS: Schaumann bodies and calcium oxalate crystals are birefringent and must not be mistaken for foreign (exogenous) material.
Although intracytoplasmic inclusions are a frequent finding in sarcoidosis, they may also be found in other granulomatous diseases, including TB, nontuberculous mycobacterial infection, leprosy, hypersensitivity pneumonitis, berylliosis, fungal infection, Crohn’s disease, foreign body granuloma (however, foreign material in sarcoidal granulomata does not exclude the diagnosis of sarcoidosis).
Examples of cell-specific intermediate filaments?
Major types of intermediate filaments are distinguished by their cell-specific expression: CKs in epithelial cells, GFAP in glial cells, desmin in skeletal/visceral/certain vascular smooth muscle cells, vimentin in cells of mesenchymal origin, and neurofilaments in neurons.
GFAP and vimentin in astroglial cells.
GFAP and vimentin form intermediate filaments in astroglial cells and modulate their motility and shape. In particular, vimentin filaments are present at early developmental stages, while GFAP filaments are characteristic of differentiated and mature brain astrocytes.
Oncotype DX (Genomic Health Inc.), MammaPrint (Agendia), Mammostrat (Clarient). How do they work?
Oncotype DX is a real-time RT-PCR assay measuring RNA expression in 16 cancer-related genes and five reference genes, using paraffin-embedded tissue. Results are given as a recurrence score between 0 and 100, which are translated as low risk (a score of 18 or lower), medium risk (19 to 30), or high risk (31 or above). MammaPrint microarray measures expression of 70 genes in fresh or FFPE tissue; it categorizes patients as either high risk, (a so-called poor signature), or low risk (a so-called good signature) for recurrence. Mammostrat is an IHC test measuring five markers: p53, HTF9C, CEACAM5, NDRG1, and SLC7A5. The results are combined into a quantitative risk index: low, moderate, and high. Oncotype DX and MammaPrint are send-out tests, with TATs of 10-14 days, while results from the IHC-based Mammostrat, also a send-out test, are available to local pathologists within 48-72 hours. As of 3/2014, only MammaPrint has FDA clearance.
Solid organ transplant-associated acute graft-versus-host disease.
The occurrence of an immunologically mediated and injurious set of reactions by cells genetically disparate to their host is known as GVHD. Acute GVHD is most commonly associated with hematopoietic stem cell transplantation (35-50%). With solid organs, the highest occurrence is with small intestine transplantation (5.6%), followed by liver transplantation (1-2%). Cases have also been reported after kidney, pancreas, heart, lung, and multivisceral transplants. The clinical presentation of solid organ transplant-associated GVHD includes skin rash (red to violet maculopapular rashes which may coalesce) and diarrhea (green, mucoid, watery, sometimes bloody), and most cases quickly advance to become a multisystem disease affecting bone marrow and other nontransplanted solid organs. The patient often dies of bleeding and infection from bone marrow failure. The mortality rate of solid organ transplant-associated GVHD ranges from 30 to >75%. In the rare reported cases after lung or pancreas transplant, the mortality rate reaches 100%. The diagnosis is based on clinical symptoms, characteristic histopathologic findings on biopsied tissues, and evidence of microchimerism of donor T cells. Solid organ transplant-associated GVHD often occurs between 2-6 weeks after liver transplantation, although this is variable with late-onset cases seen in other transplant settings.
Small intestinal bacterial overgrowth.
SIBO is a common cause of chronic diarrhea and malabsorption. It results from colonization of the proximal small bowel by gram-negative aerobic and anaerobic bacteria that are normally restricted to the colon or, less frequently, from overgrowth of oropharyngeal flora. A predisposition to SIBO exists in diverse conditions where there is altered anatomy from prior surgery (eg, blind loop syndrome) or stricture or where there is impaired gut motility and prolonged orocecal transit time. The gold standard for diagnosis is a small intestinal aspirate culture showing growth of at least 10^5 colony-forming units of bacteria per milliliter (CFU/mL) of duodenal or jejunal fluid. Cultures of small-bowel mucosal biopsies can be substituted when there are inadequate luminal secretions. Histologically, mild or moderate villous blunting is the only change seen, and this is seen in only ~50% of symptomatic pts with the culture diagnosis of SIBO. The high rate of histologically “normal” biopsies does not negate the pathogenic role of bacterial overgrowth in symptomatic pts. It has been hypothesized that excess colonic flora within the small intestine can impede fat digestion by deconjugating bile acids and hindering the formation of micelles, that these bacteria can induce vitamin B12 deficiency, and that they can result in osmotic or secretory diarrhea through the production of organic acids. All of these proposed mechanisms can coexist with microscopically health small bowel mucosa.
Splendore-Hoeppli phenomenon?
AKA asteroid bodies. The in vivo formation of intensely eosinophilic material around microorganisms or biologically intert substances.
What are general categories of disorders that show Mendelian inheritance and non-Mendelian inheritance?
Mendelian inheritance: autosomal dominant, autosomal recessive, X-linked dominant, X-linked recessive.
Non-Mendelian inheritance: multifactorial disorders, disorders affected by genomic imprinting, trinucleotide repeat disorders, mitochondrial disorders, and chromosomal instability/breakage disorders.
What is desmin?
An intermediate filament protein that is characteristically found in cardiac, smooth, and striated muscle cells. The clones D33, DEB-5, and DER-11, are the 3 most used monoclonal antibodies to desmin.
What is the epithelial-mesenchymal transition (EMT)?
A phenomenon whereby epithelial cells dissemble their junctional structures, start expressing mesenchymal proteins, remodel their extracellular matrix, and become migratory. The EMT is observed in both physiologic (embryogenesis) and pathologic (carcinogenesis) settings.
How has the grading system for GI tract NECs changed from the 2004 to 2010 WHO?
The 2010 grading system emphasizes mitotic count and Ki-67 index (It is recommended that these parameters are assessed over 50 hpf.). Grade 1 NET: < or =2% Ki-67 index. Grade 2 NET: 2-20 mitoses/10 hpf and/or 3-20% Ki-67 index. Grade 3 NET: >20 mitoses/10 hpf and/or >20% Ki-67 index. Most notably, NE lesions of the GI tract are graded and staged separately in the 2010 system. The 2004 system incorporated metastasis, gross invasion, size, vascular invasion, mitotic activity and proliferative rate, which resulted in a change in terminology from “tumor” to “carcinoma” based on the presence of metastasis for tumors of identical grade. Now, NE “tumors” represent G1 and G2 lesions, regardless of the stage.
The granularity of oncocytes is due to __.
The granularity of oncocytes is due to an excessive amount of mitochondria, resulting in an abundant acidophilic, granular cytoplasm.
The diffuse cytoplasmic positivity of chromophobe renal cell carcinoma with Hale’s colloidal iron stain is due to __.
The diffuse cytoplasmic positivity of chromophobe renal cell carcinoma with Hale’s colloidal iron stain is due to staining of acid mucopolysaccharides.
In AJCC (7th edition) staging of lung cancer: What are the tumor sizes for T1a, T1b, T2a, T2b, and T3? Direct tumor invasion into an adjacent ipsilateral lobe (i.e., invasion across a fissure) is classified as __. Multiple tumor nodules in the same lobe are classified as __. Multiple tumor nodules in the same lung but a different lobe are classified as __. Malignant pleural and pericardial effusions are classified as __. Separate tumor nodules in the contralateral lung are classified as __. Distant metastases are classified as __.
T1a is ≤2.0 cm in size, T1b is >2.0 to ≤3.0 cm in size, T2a is >3.0 to ≤5.0 cm in size, T2b is >5.0 to ≤7.0 cm in size, T3 is >7 cm in size. Direct tumor invasion into an adjacent ipsilateral lobe (i.e., invasion across a fissure) is classified as T2a. Multiple tumor nodules in the same lobe are classified as T3. Multiple tumor nodules in the same lung but a different lobe are classified as T4. Malignant pleural and pericardial effusions are classified as M1a. Separate tumor nodules in the contralateral lung are classified as M1a. Distant metastases are classified as M1b.
In AJCC (7th edition) staging of lung cancer, what are definitions of PL0, PL1, PL2, and PL3?
PL0 is defined as tumor located within the lung parenchyma or only superficially invading in the pleural connective tissue, but not beyond the elastic layer of the visceral pleura (i.e., falls short of completely traversing the elastic layer). PL1 is defined as tumor invading into the visceral pleura beyond the elastic layer, and PL2 is defined as tumor invading to the visceral pleural surface. Either PL1 or PL2 status allows classification of the primary tumor as T2. PL3 is defined as tumor invading into the parietal pleura or the chest wall, and PL3 status categorizes the tumor as T3.
Clear cell meningiomas are classified as WHO grade __.
Clear cell meningioma is a variant of meningiomas classified as WHO grade II for its propensity to recur. Similar to atypical meningiomas, recurrence can be local or distant and may have a mortality rate of up to 23%.
What are sentinel events?
A sentinel event is an unexpected occurrence involving patient death or serious physical or psychological injury. Serious injury specifically includes loss of limb or function. The phrase “or the risk thereof” includes any process variation for which a recurrence would carry a significant chance of a serious adverse outcome. In addition to patient events which fall within this definition, The Joint Commission has specifically defined the following events as Sentinel: Unanticipated death or major permanent loss of function unrelated to the natural course of the patient’s illness or underlying condition. Suicide of any inpatient or within 72 hours of discharge. Unanticipated death of a full-term infant. Abduction of an individual receiving care, treatment, or services. Discharge of an infant to the wrong family. Sexual abuse/assault including rape of any patient receiving care, treatment, or services. Hemolytic transfusion reaction involving administration of blood or blood products having major blood group incompatibilities. Invasive procedure, including surgery, on the wrong patient, wrong site, or wrong procedure. Unintended retention of a foreign object in an individual after surgery or invasive procedure. Severe neonatal hyperbilirubinemia (bilirubin >30 mg/dL). Prolonged fluoroscopy with cumulative dose >1500 rads to a single field or any delivery of radiotherapy to the wrong body region or >25% above the planned radiotherapy dose. Rape, assault (leading to death or permanent loss of function), or homicide of a staff member, licensed independent practitioner, visitor, or vendor while on site at the healthcare organization.
Define: Advance care plan.
Advance care plan: An instructional document voluntarily executed by a competent patient authorizing the provision, withholding, or withdrawal of health care if the patient’s condition is irreversible and he/she lacks capacity. It may also be used to appoint a health care agent and/or to add special instructions or limitations including organ/tissue donation.
Define: Advance directive.
Advance directive: An individual instruction (oral or written) or a written statement voluntarily executed by a competent patient relating to the subsequent provision of health care for the individual.
Define: Agent, in the context of Advance Directives.
Agent: An individual designated in an Advance Directive to make a health care decision for the individual granting the power. The Agent may make any health care decision the patient could have made for him/herself while competent.
Define: Appointment of a health care agent.
Appointment of a health care agent: A written document voluntarily executed by a competent patient appointing another person (“Agent”) to make health care decisions in the event the patient lacks capacity.
Define: Capacity, in the context of Advance Directives.
Capacity: An individual’s ability to understand the significant benefits, risks, and alternatives to proposed health care and to make and communicate a health care decision.